赛升药业(300485) - 2024年度财务决算报告

北京赛升药业股份有限公司 | 固定资产 | 476,948,391.45 | 520,791,025.05 | -8.42% | | --- | --- | --- | --- | | 在建工程 | 11,032,073.70 | 1,047,500.00 | 953.18% | | 生产性生物资产 | 7,007,245.01 | 5,533,333.36 | 26.64% | | 使用权资产 | 11,693,735.50 | 12,044,547.55 | -2.91% | | 无形资产 | 47,118,981.89 | 49,951,561.48 | -5.67% | | 开发支出 | 292,706,479.20 | 208,970,118.62 | 40.07% | | 商誉 | 21,865,087.82 | 21,865,087.82 | 0.00% | | 递延所得税资产 | 1,787,957.56 | 2,424,031.38 | -26.24% | | 其他非流动资产 | 12,162,402.33 | 11,790,983.50 | 3.15% | | 资产总计 | 3,551,8 ...